Leptomycin B (LMB) specifically binds and blocks CRM1 and potentially inhibits growth of various cancer cell lines, but its clinical development was discontinued due to significant toxicity (Newlands et al, 1996; Mutka et al, 2009; Pathria et al, 2012).
Various components of the ABC were designed and built from 1939 to 1942, but development was discontinued with the onset of World War II.
Alas, it was vaporware, and despite great hue and cry from gadget bloggers (the most influential people on the planet), development was discontinued.
Early compounds were found to produce liver toxicity, however, and development was discontinued.
It is not uncommon that some small molecules in clinical development are discontinued because of abnormal liver function as a non-target related side effect.
While tabalumab development was discontinued following insufficient efficacy observed in phase 3 RA/systemic lupus erythematosus studies, other BAFF pathway drugs are approved for (belimumab) or being investigated in (atacicept, briobacept) other autoimmune indications, and BAFF bi-specific molecules are in development.
The beneficial effects of the drug may be partly lost in the aging brain (Bishay et al, 2013), and ultimately, its development was discontinued for Alzheimer's disease because efficacy in clinical phase III trials was insufficient (Green et al, 2009).
Vorozole is a third generation, aromatase-selective AI, that entered phase 3 clinical trials, but further development was discontinued when no improvement in median survival was obtained compared to megestrol acetate.[ 45] Nonetheless, we explored the feasibility of designing a DASI that is structurally related to vorozole.
Despite later basing some Windows NT and Windows 95 developments on code written for IBM and OS/2, Microsoft soon discontinued development of further interface features for OS/2.
The biological activity of bupropion can be attributed to a significant degree to its active metabolites, in particular to S,S-hydroxybupropion. GlaxoSmithKline developed this metabolite as a separate drug called radafaxine, but discontinued development in 2006 due to "an unfavourable risk/benefit assessment".
INSPIRE PHARMACEUTICALS, Durham, N.C., discontinued development of a treatment for chronic bronchitis.
